Boston Scientific Files 8-K on Financials

Ticker: BSX · Form: 8-K · Filed: Feb 5, 2025 · CIK: 885725

Boston Scientific CORP 8-K Filing Summary
FieldDetail
CompanyBoston Scientific CORP (BSX)
Form Type8-K
Filed DateFeb 5, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-results, operations

Related Tickers: BSX

TL;DR

BSX filed an 8-K on Feb 5, 2025, detailing financial results and operations.

AI Summary

Boston Scientific Corporation filed an 8-K on February 5, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhibits. The filing details the company's status as a Delaware corporation with its principal executive offices located in Marlborough, Massachusetts.

Why It Matters

This filing provides investors with updated financial information and operational results for Boston Scientific, crucial for assessing the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of financial results and does not indicate any unusual risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Boston Scientific Corporation's results of operations and financial condition, and to provide financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 5, 2025.

Where are Boston Scientific Corporation's principal executive offices located?

Boston Scientific Corporation's principal executive offices are located at 300 Boston Scientific Way, Marlborough, Massachusetts.

What is Boston Scientific Corporation's state of incorporation?

Boston Scientific Corporation is incorporated in Delaware.

What is the SEC file number for Boston Scientific Corporation?

The SEC file number for Boston Scientific Corporation is 001-11083.

Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-02-05 06:41:47

Key Financial Figures

Filing Documents

02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 5, 2025, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2024. A copy of the release is furnished with this report as Exhibit 99.1. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

01. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Boston Scientific Corporation dated February 5, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 5, 2025 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing